ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

•The update covers the approval of time-limited ibrutinib–venetoclax in first line and new data on MRD-driven treatment.•It also covers the approval of the BTKi zanubrutinib in both treatment-naive and relapsed or refractory CLL.•Additional evidence on the time-limited combination of venetoclax plus an anti-CD20 antibody in the first line are included.•Options for later-line treatments based on the type of prior lines of treatment are also included.